Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Lixiana
Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-127808 · Präparat HOS-096471
Edoxaban 30 mg once daily must be administered during concomitant use with the following P-gp
inhibitors:
• Ciclosporin: Concurrent administration of a single dose of ciclosporin 500 mg with a single
dose of edoxaban 60 mg increased edoxaban AUC and maximum serum concentration (Cmax) by
73% and 74%, respectively.
• Dronedarone: Dronedarone 400 mg twice daily for 7 days with a single concomitant dose of
edoxaban 60 mg on day 5 increased edoxaban AUC and Cmax by 85% and 46%, respectively.
• Erythromycin: Erythromycin 500 mg four times daily for 8 days with a single concomitant dose
of edoxaban 60 mg on day 7 increased the edoxaban AUC and Cmax by 85% and 68%,
respectively.
• Ketoconazole: Ketoconazole 400 mg once daily for 7 days with a single concomitant dose of
edoxaban 60 mg on day 4, increased edoxaban AUC and Cmax by 87% and 89%, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) ketoconazole (HOS-084513) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T13:11:00Z · SHA-256 5fd1fde6f72bf5d3892ddc2d35b116dd396f6657ffdfad7faca24bdcd927d334 · Passage 8990dfecc898dc8451e4a9c6f84aebadbfe6f58e86582291568022d4c188fdc5 · Zeichen 961–1881 im Abschnitt
Wechselwirkungen · Cerdelga
Cerdelga 21 mg hard capsules Cerdelga 84 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-130410 · Präparat HOS-096915
At 84 mg twice daily dosing with eliglustat in non-PMs, it is predicted that concomitant use of
moderate CYP2D6 inhibitors (e.g., duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet,
dronedarone) would increase eliglustat exposure approximately up to 4-fold. Caution should be used
with moderate CYP2D6 inhibitors in IMs and EMs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) duloxetine (HOS-089666) moclobemide (HOS-087879) terbinafine (HOS-113069) mirabegron (HOS-125567) cinacalcet (HOS-128604) eliglustat (HOS-130401)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-27T15:21:00Z · SHA-256 1c727ba97e10c9a78b07345b037b7efc3b42bce5b1ed72eaf8881cd34d7be69a · Passage 3831c61468b9bb47d8b05d1cccc7b17f7e2e31bf194bba2a0f0a19bda87451af · Zeichen 1558–1896 im Abschnitt
Wechselwirkungen · Imbruvica
IMBRUVICA 140 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-131610 · Präparat HOS-097103
Moderate CYP3A4 inhibitors
In patients with B-cell malignancies taking IMBRUVICA with food, co-administration of the
CYP3A4 inhibitor erythromycin increased Cmax by 3.4-fold and AUC by 3.0-fold. If a moderate
CYP3A4 inhibitor (e.g., fluconazole, erythromycin, amprenavir, aprepitant, atazanavir, ciprofloxacin,
crizotinib, diltiazem, fosamprenavir, imatinib, verapamil, amiodarone and dronedarone) is indicated,
reduce IMBRUVICA dose to 280 mg (two capsules) for the duration of the inhibitor use. Monitor
patient closely for toxicity and follow dose modification guidance as needed (see sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) atazanavir (HOS-086180) dronedarone (HOS-086144) ciprofloxacin (HOS-085177) crizotinib (HOS-116818) aprepitant (HOS-112506) imatinib (HOS-110212) fluconazole (HOS-087945) erythromycin (HOS-084514) amprenavir (HOS-086183) fosamprenavir (HOS-086182) amiodarone (HOS-085596) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T15:30:00Z · SHA-256 a9cee31168a81381e2e0315390c7e6008548b2272679979bce5eb1784595366b · Passage 1721a0def4de8056f7e10f969c4b7ccfd08580bc7211226c9b15729a1f4d9274 · Zeichen 1385–1995 im Abschnitt
Wechselwirkungen · Imbruvica
IMBRUVICA 140 mg film-coated tablets IMBRUVICA 280 mg film-coated tablets IMBRUVICA 420 mg film-coated tablets IMBRUVICA 560 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52
HOS-131641 · Präparat HOS-097103
Moderate CYP3A4 inhibitors
In patients with B-cell malignancies taking IMBRUVICA with food, co-administration of the
CYP3A4 inhibitor erythromycin increased Cmax by 3.4-fold and AUC by 3.0-fold. If a moderate
CYP3A4 inhibitor (e.g., fluconazole, erythromycin, amprenavir, aprepitant, atazanavir, ciprofloxacin,
crizotinib, diltiazem, fosamprenavir, imatinib, verapamil, amiodarone and dronedarone) is indicated,
reduce IMBRUVICA dose to 280 mg for the duration of the inhibitor use. Monitor patient closely for
toxicity and follow dose modification guidance as needed (see sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) atazanavir (HOS-086180) dronedarone (HOS-086144) ciprofloxacin (HOS-085177) crizotinib (HOS-116818) aprepitant (HOS-112506) imatinib (HOS-110212) fluconazole (HOS-087945) erythromycin (HOS-084514) amprenavir (HOS-086183) fosamprenavir (HOS-086182) amiodarone (HOS-085596) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T15:30:00Z · SHA-256 a9cee31168a81381e2e0315390c7e6008548b2272679979bce5eb1784595366b · Passage 11d78adc16a783699eb7f1576857ba9f5b37c676bc8e12576d76565938afe7b7 · Zeichen 1426–2021 im Abschnitt
Gegenanzeigen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-132828 · Präparat HOS-097310
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1;
- Hypersensitivity to any imidazole antifungal medicinal product;
- Acute or chronic liver disease and/or if pre-treatment liver enzymes levels are above 2 times the upper
limit of normal (see sections 4.2 and 4.4):
- Pregnancy (see section 4.6);
- Breastfeeding (see section 4.6);
- Congenital or documented acquired QTc prolongation ;
- Concomitant therapy with any of the following medicinal products which may interact and result in
potentially life-threatening adverse reactions (see section 4.5):
o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and
lovastatin) due to an increased risk of skeletal muscle toxicity including rhabdomyolysis;
o eplerenone due to an increased risk of hyperkalemia and hypotension;
o substances that may have their plasma concentrations increased and have QT prolonging potential:
methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir
(saquinavir/ritonavir 1000/100 mg bid), ranolazine, mizolastine, halofantrine;
o dabigatran due to an increased bleeding risk;
o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and
respiratory depression;
o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and
methylergometrine (methylergonovine) due to an increased risk of ergotism and other serious
vasospastic adverse reactions;
o lurasidone;
o quetiapine due to an increased risk of toxicity;
o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk
of hepatotoxicity and QT interval prolongation;
o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure;
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) methylergonovine (HOS-086155) dronedarone (HOS-086144) methadone (HOS-086198) lovastatin (HOS-086157) eplerenone (HOS-089050) atorvastatin (HOS-086304) felodipine (HOS-108908) alprazolam (HOS-086171) halofantrine (HOS-085606) simvastatin (HOS-086158) quinidine (HOS-085593) dabigatran (HOS-112096) ergot alkaloids (HOS-108807) imidazole (HOS-117862) disopyramide (HOS-085595) telithromycin (HOS-084523) saquinavir (HOS-084522) clarithromycin (HOS-084517) pimozide (HOS-085600) nisoldipine (HOS-114251) ergotamine (HOS-086154) ritonavir (HOS-084521) lurasidone (HOS-086148) ranolazine (HOS-086141) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167) mizolastine (HOS-085609)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage f9d16641f2e5b06b321fa0c79f0dacdfede818d20585398b4d37ddb19dad6a14 · Zeichen 0–2044 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-132842 · Präparat HOS-097310
o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and lovastatin)
due to an increased risk of skeletal muscle toxicity including rhabdomyolysis;
o eplerenone due to an increased risk of hyperkalemia and hypotension;
o substances that may have their plasma concentrations increased and have QT prolonging potential :
methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir (saquinavir/ritonavir
1000/100 mg bid), ranolazine, mizolastine, halofantrine;
o dabigatran due to an increased bleeding risk;
o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and
respiratory depression;
o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine
(methylergonovine) due to an increased risk of ergotism and other serious vasospastic adverse
reactionsevents
o lurasidone;
o quetiapine due to an increased risk of toxicity;
o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk of
hepatotoxicity and QT interval prolongation;
o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure;
o colchicine in patients with renal impairment due to an increased risk of severe adverse reactions;
o irinotecan due to an alteration of the metabolism of this medicinal product;
o everolimus, sirolimus (also known as rapamycin) due to an increase of the plasma concentrations of
these medicinal products;
o vardenafil in men older than 75-years due to increased risk of adverse reactions
o paritaprevir/ombitasvir (ritonavir) due to increased risk of adverse reactions;
o fesoterodine and solifenacin in patients with renal impairment;
o tolvaptan used for a specific disease called “syndrome of inappropriate antidiuretic hormone
secretion”.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) solifenacin (HOS-116433) methylergonovine (HOS-086155) dronedarone (HOS-086144) methadone (HOS-086198) lovastatin (HOS-086157) eplerenone (HOS-089050) atorvastatin (HOS-086304) felodipine (HOS-108908) alprazolam (HOS-086171) halofantrine (HOS-085606) simvastatin (HOS-086158) quinidine (HOS-085593) dabigatran (HOS-112096) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) disopyramide (HOS-085595) telithromycin (HOS-084523) saquinavir (HOS-084522) ombitasvir (HOS-110300) clarithromycin (HOS-084517) pimozide (HOS-085600) nisoldipine (HOS-114251) colchicine (HOS-086147) everolimus (HOS-086310) fesoterodine (HOS-116432) sirolimus (HOS-085172) ergotamine (HOS-086154) ritonavir (HOS-084521) paritaprevir (HOS-110301) lurasidone (HOS-086148) ranolazine (HOS-086141) irinotecan (HOS-112102) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167) mizolastine (HOS-085609) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 0b65d259964c6f340994be44a864bad55b31283e3fc412d0d5a47323a792d889 · Zeichen 171–2105 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-132854 · Präparat HOS-097310
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Analgesic opioid
Methadone Potential ↑ in plasma concentrations of Contraindicated due to the increased
methadone risk of serious cardiovascular events
including QT prolongation and
torsade de pointes, or respiratory or
CNS depression (see section 4.3).
Buprenorphine IV and Buprenorphine: Careful monitoring.
sublingual AUC: ↑ 1.5-fold The buprenorphine dose should be
Cmax: ↑1.7-fold adjusted.
Alfentanil, fentanyl Potential ↑in plasma concentrations of Careful monitoring of adverse
alfentanil and fentanyl reactions (respiratory depression,
sedation) is recommended. It may be
necessary to lower the dose of
alfentanil and fentanyl.
Oxycodone ↑in plasma concentrations of oxycodone Careful monitoring.
have been observed The oxycodone dose may be
adjusted.
Antiarrhythmics
Disopyramide Potential ↑in plasma concentrations of Contraindicated due to the risk of
Quinidine disopyramide and quinidine serious cardiovascular events
including QT prolongation (see
Dronedarone Repeated doses of 200 mg ketoconazole section 4.3).
daily resulted in a 17-fold increase in
dronedarone exposure
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) dronedarone (HOS-086144) methadone (HOS-086198) oxycodone (HOS-109487) quinidine (HOS-085593) buprenorphine (HOS-086193) disopyramide (HOS-085595) fentanyl (HOS-086196)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage a1dd81238eab9495ccc07c3bae05807a0a25b388887cce3d7c2818dcf0cb8b03 · Zeichen 5148–7488 im Abschnitt
Gegenanzeigen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 5
HOS-134441 · Präparat HOS-097580
Co-administration of darunavir with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) bepridil (HOS-085612) quinidine (HOS-085593) domperidone (HOS-114656) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 0623acf1b29e890c85fc94e283370387704b0e29df5d70432cea48b4e0948b1f · Zeichen 452–1192 im Abschnitt
Gegenanzeigen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 44
HOS-134580 · Präparat HOS-097580
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the co-
administered medicinal product. Therefore, concomitant treatment with such medicinal products for
which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cobicistat (HOS-088111) bepridil (HOS-085612) quinidine (HOS-085593) grazoprevir (HOS-108815) ivabradine (HOS-109426) colchicine (HOS-086147) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) ranolazine (HOS-086141) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage dc54d993409459377eca2778cf25b8655b8f68649a72da054ab0f0fc3b77b4d4 · Zeichen 1379–2234 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-134490 · Präparat HOS-097580
Amiodarone Darunavir co-administered with low
Bepridil dose ritonavir and amiodarone,
Dronedarone bepridil, dronedarone, ivabradine,
Ivabradine, quinidine, or ranolazine is
Quinidine contraindicated (see section 4.3).
Ranolazine
Digoxin digoxin AUC ↑ 61% Given that digoxin has a narrow
0.4 mg single dose digoxin Cmin ND therapeutic index, it is
digoxin Cmax ↑ 29% recommended that the lowest
(↑ digoxin from probable inhibition of possible dose of digoxin should
P-gp) initially be prescribed in case
digoxin is given to patients on
darunavir/ritonavir therapy. The
digoxin dose should be carefully
titrated to obtain the desired clinical
effect while assessing the overall
clinical state of the subject.
ANTIBIOTIC
clarithromycin AUC ↑ 57%
Clarithromycin 500 mg Caution should be exercised when
twice daily clarithromycin Cmin ↑ 174% clarithromycin is combined with
clarithromycin Cmax ↑ 26% darunavir co-administered with low
#
darunavir AUC ↓ 13% dose ritonavir.
#
darunavir Cmin ↑ 1%
#
darunavir Cmax ↓ 17% For patients with renal impairment
the Summary of Product
14-OH-clarithromycin concentrations
Characteristics for clarithromycin
were not detectable when combined
should be consulted for the
with darunavir/ritonavir.
recommended dose.
(↑ clarithromycin from CYP3A
inhibition and possible P-gp inhibition)
ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR
Apixaban Not studied. Co-administration of The use of boosted darunavir with a
Rivaroxaban boosted darunavir with these direct anticoagulant (DOAC) that is
anticoagulants may increase metabolized by CYP3A4 and
concentrations of the anticoagulant. transported by P-gp is not
(CYP3A and/or P-gp inhibition). recommended as this may lead to an
increased bleeding risk.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) rivaroxaban (HOS-086236) lead (HOS-085592) clarithromycin (HOS-084517) apixaban (HOS-112091) ivabradine (HOS-109426) ritonavir (HOS-084521) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage b65eedd477845abe8a7750326e8baec6a95ff9f96def3bed8da0053e87d29a9b · Zeichen 21061–24601 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-134613 · Präparat HOS-097580
53
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
HIV Protease inhibitors (PIs) - with co-administration of low dose ritonavir†
Lopinavir/ritonavir 400/100 lopinavir AUC ↑ 9% Due to a decrease in the exposure
mg twice daily lopinavir Cmin ↑ 23% (AUC) of darunavir by 40%,
lopinavir Cmax ↓ 2% appropriate doses of the combination
have not been established. Hence,
darunavir AUC ↓ 38%‡ concomitant use of boosted darunavir
darunavir Cmin ↓ 51%‡ and the combination product
darunavir Cmax ↓ 21%‡ lopinavir/ritonavir is contraindicated
Lopinavir/ritonavir lopinavir AUC ↔ (see section 4.3).
533/133.3 mg twice daily lopinavir Cmin ↑ 13%
lopinavir Cmax ↑ 11%
darunavir AUC ↓ 41%
darunavir Cmin ↓ 55%
darunavir Cmax ↓ 21%
‡
based upon non dose normalised
values
CCR5 ANTAGONIST
Maraviroc maraviroc AUC ↑ 305% The maraviroc dose should be 150
150 mg twice daily maraviroc Cmin ND mg twice daily when co-administered
maraviroc Cmax ↑ 129% with boosted darunavir.
darunavir, ritonavir concentrations
were consistent with historical data
α1-ADRENORECEPTOR ANTAGONIST
Alfuzosin Based on theoretical considerations Co-administration of boosted
darunavir is expected to increase darunavir and alfuzosin is
alfuzosin plasma concentrations. contraindicated (see section 4.3).
(CYP3A inhibition)
ANAESTHETIC
Alfentanil Not studied. The metabolism of The concomitant use with boosted
alfentanil is mediated via CYP3A, darunavir may require to lower the
and may as such be inhibited by dose of alfentanil and requires
boosted darunavir. monitoring for risks of prolonged or
delayed respiratory depression.
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. Boosted darunavir is Caution is warranted and ther apeutic
Flecainide expected to increase these concentration monitoring, if
Lidocaine (systemic) antiarrhythmic plasma available, is recommended for these
Mexiletine concentrations. antiarrhythmics when co-
Propafenone (CYP3A and/or CYP2D6 administered with boosted darunavir.
inhibition)
Amiodarone Bepridil Co-administration of boosted
Dronedarone Ivabradine darunavir and amiodarone, bepridil,
Quinidine Ranolazine dronedarone, ivabradine, quinidine,
or ranolazine is contraindicated (see
section 4.3).
Digoxin digoxin AUC ↑ 61% Given that digoxin has a narrow
0.4 mg single dose digoxin Cmin ND therapeutic index, it is recommended
digoxin Cmax ↑ 29% that the lowest possible dose of
(↑ digoxin from probable inhibition digoxin should initially be prescribed
of P-gp) in case digoxin is given to patients on
boosted darunavir therapy. The
digoxin dose should be carefully
titrated to obtain the desired clinical
effect while assessing the overall
clinical state of the subject.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) lopinavir (HOS-086269) propafenone (HOS-084530) dronedarone (HOS-086144) protease (HOS-085623) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) disopyramide (HOS-085595) maraviroc (HOS-086186) ivabradine (HOS-109426) ritonavir (HOS-084521) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 737ba554b4078e65ecf09cd520335cc5df12785cb4f30673452d55d887588655 · Zeichen 22720–27726 im Abschnitt
Gegenanzeigen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-138460 · Präparat HOS-098200
Co-administration with medicinal products such as those products listed below due to the potential for
serious and/or life-threatening adverse reactions (see section 4.5):
- alfuzosin
- amiodarone, dronedarone, ivabradine, quinidine, ranolazine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- rifampicin
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- dapoxetine
- domperidone
- naloxegol
- pimozide, quetiapine, sertindole, lurasidone (see section 4.5)
- elbasvir/grazoprevir
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) sildenafil (HOS-086162) ergotamine (HOS-086154) amiodarone (HOS-085596) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage d5339bf98a1f0c8c12e608ac2e03423cce35d78a9e0bb8d544d94fd38d39e9f0 · Zeichen 452–1349 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-138479 · Präparat HOS-098200
9
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Based on theoretical Caution is warranted and
Flecainide considerations DRV/COBI is concentration monitoring, if
Mexiletine expected to increase these available, is recommended for
Propafenone antiarrhythmic plasma these antiarrhythmics when
Lidocaine (systemic) concentrations. co-administered with Symtuza.
(CYP3A inhibition)
Co-administration of
Amiodarone amiodarone, dronedarone,
Dronedarone ivabradine, quinidine, or
Ivabradine ranolazine and Symtuza is
Quinidine contraindicated (see section 4.3).
Ranolazine
Digoxin Based on theoretical It is recommended that the lowest
considerations DRV/COBI is possible dose of digoxin should
expected to increase digoxin initially be given to patients on
plasma concentrations. Symtuza. The digoxin dose
(P-glycoprotein inhibition) should be carefully titrated to
obtain the desired clinical effect
while assessing the overall
clinical state of the subject.
ANTIBIOTIC
Clarithromycin Based on theoretical Caution should be exercised
considerations clarithromycin is when clarithromycin is combined
expected to increase darunavir with Symtuza.
and/or cobicistat plasma
concentrations. For patients with renal
(CYP3A inhibition) impairment the Summary of
Concentrations of clarithromycin Product Characteristics for
may be increased upon clarithromycin should be
co-administration with consulted for the recommended
DRV/COBI. dose.
(CYP3A inhibition)
ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR
Apixaban Based on theoretical Co-administration of Symtuza
Rivaroxaban considerations co-administration of with a direct oral anticoagulant
Symtuza with these anticoagulants (DOAC) that is metabolised by
may increase concentrations of the CYP3A4 and transported by P-gp
anticoagulant. is not recommended as this may
(CYP3A and/or P-glycoprotein lead to an increased bleeding
inhibition) risk.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) dronedarone (HOS-086144) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) quinidine (HOS-085593) digoxin (HOS-086172) rivaroxaban (HOS-086236) lead (HOS-085592) disopyramide (HOS-085595) clarithromycin (HOS-084517) apixaban (HOS-112091) ivabradine (HOS-109426) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 16be5409503bc03e649799dffc8cd2afca527a103a3ef9517c3e4820acf237b6 · Zeichen 7326–10593 im Abschnitt
Wechselwirkungen · Maviret
Maviret 100 mg/40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-139031 · Präparat HOS-098268
Glecaprevir and pibrentasvir are substrates of the efflux transporters P-gp and/or BCRP. Glecaprevir is
also a substrate of the hepatic uptake transporters OATP1B1/3. Co-administration of Maviret with
medicinal products that inhibit P-gp and BCRP (e.g. ciclosporin, cobicistat, dronedarone, itraconazole,
ketoconazole, ritonavir) may slow elimination of glecaprevir and pibrentasvir and thereby increase
plasma exposure of the antivirals. Medicinal products that inhibit OATP1B1/3 (e.g. elvitegravir,
ciclosporin, darunavir, lopinavir) increase systemic concentrations of glecaprevir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) dronedarone (HOS-086144) ketoconazole (HOS-084513) cobicistat (HOS-088111) itraconazole (HOS-084516) darunavir (HOS-086181) ritonavir (HOS-084521) elvitegravir (HOS-088110)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-15T12:56:00Z · SHA-256 225c0ba8f2354e64e1131849dc7b6e23a86b099b858b5f9e8bda200a3bdf07cd · Passage 9a0f0abfcd319c2a79d78707d10beaeb48a526add61241c9553dac35271a0100 · Zeichen 2243–2827 im Abschnitt
Wechselwirkungen · Maviret
Maviret 50 mg/20 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 32
HOS-139082 · Präparat HOS-098268
Glecaprevir and pibrentasvir are substrates of the efflux transporters P-gp and/or BCRP. Glecaprevir is
also a substrate of the hepatic uptake transporters OATP1B1/3. Co-administration of Maviret with
medicinal products that inhibit P-gp and BCRP (e.g. ciclosporin, cobicistat, dronedarone, itraconazole,
ketoconazole, ritonavir) may slow elimination of glecaprevir and pibrentasvir and thereby increase
plasma exposure of the antivirals. Medicinal products that inhibit OATP1B1/3 (e.g. elvitegravir,
ciclosporin, darunavir, lopinavir) increase systemic concentrations of glecaprevir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) dronedarone (HOS-086144) ketoconazole (HOS-084513) cobicistat (HOS-088111) itraconazole (HOS-084516) darunavir (HOS-086181) ritonavir (HOS-084521) elvitegravir (HOS-088110)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-15T12:56:00Z · SHA-256 225c0ba8f2354e64e1131849dc7b6e23a86b099b858b5f9e8bda200a3bdf07cd · Passage 9a0f0abfcd319c2a79d78707d10beaeb48a526add61241c9553dac35271a0100 · Zeichen 2302–2886 im Abschnitt
Wechselwirkungen · Biktarvy
Biktarvy 30 mg/120 mg/15 mg film-coated tablets Biktarvy 50 mg/200 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-139270 · Präparat HOS-098314
Bictegravir is both a P-gp and a BCRP substrate. The clinical relevance of this feature is not
established. Therefore, caution is recommended when bictegravir is combined with medicinal
products known to inhibit P-gp and/or BCRP (e.g. macrolides, ciclosporin, verapamil, dronedarone,
glecaprevir/pibrentasvir) (see also table below).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T17:05:00Z · SHA-256 8ec4738243d92aa421e74b71a9bad453e15421c1f952d3be4e88479f189e0fe4 · Passage 10ae8dc749a9b1954cc07201df3e94dfbb081142421a7e6fde1ad1f5ee15be7d · Zeichen 921–1254 im Abschnitt
Wechselwirkungen · Talzenna
Talzenna 0.1 mg hard capsules Talzenna 0.25 mg hard capsules Talzenna 0.35 mg hard capsules Talzenna 0.5 mg hard capsules Talzenna 1 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-140563 · Präparat HOS-098546
Concomitant use of strong P-gp inhibitors (including but not limited to amiodarone, carvedilol,
clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir, itraconazole,
ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, telaprevir,
tipranavir, and verapamil) should be avoided. If co-administration with a strong P-gp inhibitor is
unavoidable, the Talzenna dose should be reduced (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) propafenone (HOS-084530) dronedarone (HOS-086144) ketoconazole (HOS-084513) carvedilol (HOS-115322) cobicistat (HOS-088111) quinidine (HOS-085593) telaprevir (HOS-090618) lapatinib (HOS-122565) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) erythromycin (HOS-084514) darunavir (HOS-086181) ritonavir (HOS-084521) amiodarone (HOS-085596) ranolazine (HOS-086141) tipranavir (HOS-086184) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-18T15:15:00Z · SHA-256 ed4d297943838ad90546bb310100bb9880e0b3c9833c452b88d5862d4841e255 · Passage 234ecfeab8722ea5160a874b4a7240829c7b65e708ad9e195210f3f70d12f3a4 · Zeichen 1803–2263 im Abschnitt
Wechselwirkungen · Brukinsa
BRUKINSA 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-143676 · Präparat HOS-099032
If a moderate CYP3A inhibitor must be used (e.g., erythromycin, ciprofloxacin, diltiazem,
dronedarone, fluconazole, verapamil, aprepitant, imatinib, grapefruit juice, Seville oranges), the
BRUKINSA dose should be reduced to 160 mg (two capsules) for the duration of the inhibitor use.
Patients should be closely monitored for toxicity and dose modification guidance should be followed
as needed (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) dronedarone (HOS-086144) ciprofloxacin (HOS-085177) aprepitant (HOS-112506) grapefruit juice (HOS-088787) imatinib (HOS-110212) fluconazole (HOS-087945) erythromycin (HOS-084514) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T17:42:00Z · SHA-256 f0ac9353445e35e4a8c825c9d83ba5a8a9959280674f31c13eb499d959c0d4e9 · Passage 0e899e68c42867628ce3269115d0a815c86c24327d2d9e1b292cd50c1e21fe03 · Zeichen 1467–1880 im Abschnitt
Wechselwirkungen · Brukinsa
BRUKINSA 160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 32
HOS-143736 · Präparat HOS-099032
If a moderate CYP3A inhibitor must be used (e.g., erythromycin, ciprofloxacin, diltiazem,
dronedarone, fluconazole, verapamil, aprepitant, imatinib, grapefruit juice, Seville oranges), reduce
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) dronedarone (HOS-086144) ciprofloxacin (HOS-085177) aprepitant (HOS-112506) grapefruit juice (HOS-088787) imatinib (HOS-110212) fluconazole (HOS-087945) erythromycin (HOS-084514) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T17:42:00Z · SHA-256 f0ac9353445e35e4a8c825c9d83ba5a8a9959280674f31c13eb499d959c0d4e9 · Passage b5252cc70f292d34507f592624d97a267f663d21edddd35da2de4eb207cca711 · Zeichen 1472–1663 im Abschnitt
Wechselwirkungen · Rivaroxaban Accord
Rivaroxaban Accord 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-145743 · Präparat HOS-099403
Given the limited clinical data available with dronedarone, co-administration with rivaroxaban should be
avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-28T12:05:00Z · SHA-256 2ea30fcd4accd6d6282f12bcc626df889eea5534ed279adc61cf509cb720cb5e · Passage bcbbe9aedbc4d4653bf86c2bc431d3b57ee6a3f1ab2f668718c243e36c041571 · Zeichen 2409–2522 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.